このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Boryung マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Jay Kim

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 09

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Jan 25

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

Jan 10

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Dec 23

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Dec 08

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Nov 23

CEO（最高経営責任者

Jay Kim

no data

在職期間

Mr. Jay Kim serves as Chief Executive Officer of Boryung Corporation.

Boryung マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Boryung Corporation, Annual General Meeting, Mar 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Boryung Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

Full year 2023 earnings: EPS misses analyst expectations

Boryung Corporation, Annual General Meeting, Mar 26, 2024

Upcoming dividend of ₩100.00 per share at 0.9% yield

Boryung Corporation(KOSE:A003850) dropped from KOSPI 200 Index

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Boryung Corporation Partners with Axiom Space and Aurelia Institute to Launch the "2023 Humans in Space" Program

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of ₩100.00 per share

Less than half of directors are independent

Price target decreased to ₩15,500

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Upcoming dividend of ₩75.77 per share

Price target increased to ₩17,500

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS ₩400 (vs ₩180 in 1Q 2020)

Investor sentiment deteriorated over the past week

A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Full year 2020 earnings released: EPS ₩554 (vs ₩698 in FY 2019)

Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Boryung Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

New 90-day high: ₩20,500

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Market pulls back on stock over the past week

Price target raised to ₩21,000

New 90-day high: ₩20,700

Market bids up stock over the past week

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Third quarter 2020 earnings released: EPS ₩168

New 90-day low: ₩14,750

New 90-day low: ₩15,250

Price target raised to ₩21,000

First half earnings released

New 90-day high - ₩17,550

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04